Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab functional respiratory imaging study in severe eosinophilic asthma
NL-OMON55135Active, not recruiting
- Sponsor
- Longfonds
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by Longfonds. Primary endpoints: Absolute change in specific airway volume at 12 weeks and Absolute change in specific airway resistance at 12 weeks. Started Nov 2021; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON55135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55135.